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Antibiotics used by general practitioners frequently appear in adverse-event reports of drug-induced hepato-
toxicity. Most cases are idiosyncratic (the adverse reaction cannot be predicted from the drug’s pharmacologi-
cal proﬁle or from pre-clinical toxicology tests) and occur via an immunological reaction or in response to the
presence of hepatotoxic metabolites. With the exception of trovaﬂoxacin and telithromycin (now severely
restricted), hepatotoxicity crude incidence remains globally low but variable. Thus, amoxicillin/clavulanate
and co-trimoxazole, as well as ﬂucloxacillin, cause hepatotoxic reactions at rates that make them visible in
general practice (cases are often isolated, may have a delayed onset, sometimes appear only after cessation
of therapy and can produce an array of hepatic lesions that mirror hepatobiliary disease, making causality often
difﬁcult to establish). Conversely, hepatotoxic reactions related to macrolides, tetracyclines and ﬂuoroquino-
lones (in that order, from high to low) are much rarer, and are identiﬁable only through large-scale studies
or worldwide pharmacovigilance reporting. For antibiotics speciﬁcally used for tuberculosis, adverse effects
range from asymptomatic increases in liver enzymes to acute hepatitis and fulminant hepatic failure. Yet, it
is difﬁcult to single out individual drugs, as treatment always entails associations. Patients at risk are mainly
those with previous experience of hepatotoxic reaction to antibiotics, the aged or those with impaired
hepatic function in the absence of close monitoring, making it important to carefully balance potential risks
with expected beneﬁts in primary care. Pharmacogenetic testing using the new genome-wide association
studies approach holds promise for better understanding the mechanism(s) underlying hepatotoxicity.
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Introduction
Antibiotics are considered as a common cause of drug-induced
liver injury (DILI).
1–3 Although the frequency of serious
antibiotic-induced hepatotoxicity is low compared with the
amounts prescribed each year—population-based estimates
suggest that it occurs in ,5 per 100000 population
4—it
remains a main reason for antibiotic withdrawal after product
launch. Antibiotic-induced hepatotoxicity is usually asympto-
matic, transient and associated with only mild hepatic impair-
ment.
5 In rare cases, however, signiﬁcant morbidity,
6,7 the
need for liver transplantation
7,8 and death from acute liver
failure
7–9 have been reported. In recent years, the European
Medicines Agency (EMA) and the US FDA have addressed these
issues by putting emphasis on both pre-clinical (to detect
signals) and clinical studies.
10 Nonetheless, predicting what
hepatotoxicity will be after approval based on data assembled
during drug development remains a risky exercise.
Public awareness of antibiotic-induced hepatotoxicity has,
however, increased over recent years (following actions of regu-
latory bodies targeting speciﬁc antibiotics),
11,12 making it essen-
tial for the primary care physician to better identify and minimize
the risk of serious liver damage with existing agents.
2,5 In the
present review, we describe the adverse hepatic effects of anti-
biotics, including their frequency, severity and clinico-
pathological features, and discuss these observations within
the context of the primary care setting. Indeed, this is not only
where antibiotic consumption is greatest
13–15 but also where
risks are highest, given the inherent difﬁculties of rapid access
to in-depth biological investigations for prompt diagnosis. As a
source of information, we ﬁrst searched electronically the
online version of the US National Library of Medicine (Bethesda,
MD, USA; http://www.pubmed.com) for original research papers,
case reports and reviews published until the end of February
2011. For antibiotics used primarily for non-tuberculosis
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1431indications, the search terms were ‘hepatic adverse event OR
hepatotoxicity AND ,each of the following terms.’: ‘beta-
lactam*’; ‘macrolid*’; ‘(sulfonamide OR sulphonamide)’; ‘tetracy-
clin*’; ‘ﬂuoroquinolon*’; ‘amoxycillin*’; ‘clavulanic’; ‘telithromycin’;
‘clarithromycin’; ‘azithromycin’; ‘erythromycin’; ‘levoﬂoxacin’;
‘moxiﬂoxacin’; ‘gatiﬂoxacin’; and ‘trovaﬂoxacin’, with restriction
to papers dealing with antibiotic-induced hepatotoxicity. For
hepatotoxicity related to antibiotics used for the treatment of
tuberculosis, the search terms were ‘hepatotoxicity AND ,each
of the following terms.’: ‘anti-tuberculosis agents’; ‘ethambu-
tol’; ‘isoniazid’; ‘pyrazinamide’; ‘(rifampicin OR rifampin)’; and
‘streptomycin’, with focus on papers published within the last
10 years. Reference lists from review papers were examined for
additional relevant articles. Current prescribing information and
regulatory documents from both the FDA and the EMA were
also systematically retrieved and examined.
Identifying antibiotic-induced liver injury
Signs and symptoms of hepatotoxic reactions
Most cases of antibiotic-induced hepatotoxicity are idiosyncratic
(the adverse reaction occurs in a very small proportion
of patients, cannot be predicted either from the drug’s
pharmacology or from pre-clinical toxicology tests and is host
dependent).
2,4,16 It is thought to occur either via an immunologi-
cal reaction, including concomitant liver inﬂammation associated
with viral or bacterial infection of liver or inﬂammatory disease,
17
in response to hepatotoxic metabolites,
18 or, as more recently
suggested, when the drug synergizes with lipopolysaccharide-
induced inﬂammatory cytokine signalling to cause acute hepato-
cyte death.
17,19 Symptoms are similar to those of other liver dis-
eases, and include jaundice, malaise, abdominal pain,
unexplained nausea and anorexia.
2 Because antibiotic-induced
hepatotoxicitymimicsotherliverdiseases,diagnosisisnecessarily
one ofelimination and is usually based on a high degree ofclinical
suspicion following exclusion of competing aetiologies, such as
viral hepatitis or biliary disease.
18 Clues suggestive of drug
allergy include rash, fever or eosinophilia, duration of exposure
of 1–5 weeks and an often rapid response following
re-administration of the antibiotic.
2,18,20
Risk factors and early detection
In cases of suspected liver reactions, it is essential to obtain a
detailed drug history that includes awareness of the drug’s hepa-
totoxic potential, the timing of drug administration in relation to
the emergence of symptoms, previous administration of the anti-
biotic in question and concomitant drug use (including alternative
or herbal medications).
18,20,21 Antibiotic-induced hepatotoxicity
can often be detected early from elevations in serum alanine ami-
notransferase (ALT) levels,
18 where these exceed twice the upper
limit of normal (ULN).
20,22–24 Clinically signiﬁcant rises in ALT
accompanied by jaundice (bilirubin level ≥2×ULN) suggest a
worse prognosis compared with elevated ALT alone,
9 with the
combination of hepatocellular injury (ALT .3×ULN) and jaundice
(bilirubin .2×ULN) being associated with  10% mortality (Hy’s
Law).
7,25 Because of the short-term nature of protocols in clinical
trials of antibiotics, these changes may remain unseen for a drug
later proven to be hepatotoxic.
26
Several factors, however, complicate the picture. First, host
factors such as age, pre-existing liver disease, concurrent medi-
cations and excessive alcohol consumption may all increase sus-
ceptibility to drug-induced hepatotoxicity,
20 although the nature
of their interaction with antibiotics to increase the risk of hepato-
toxicity is uncertain. General practitioners should be aware that
while age is often considered a risk factor, children and adoles-
cents mayalso be affected by the same drugs as adults.
27 Predis-
posing factors, including the concomitant use of acetaminophen
(paracetamol), may affect biochemical tests, while infection,
especially sepsis, may cause liver toxicity usually in the form of
cholestasis. Second, hepatotoxicity seems often related to the
administration of large doses of any drug, with 77% of DILI
cases included in the Swedish registry occurring with drugs admi-
nisteredatdosagesof.50 mg/day.
28Inthecontextofantibiotics,
this means that the large daily dosages that may be essential
today to keep pace with the decreased susceptibility of the main
targetorganisms(e.g.Streptococcuspneumoniaeversusamoxicil-
lin) will increase the risk in a non-speciﬁc fashion, dependent on
the local epidemiology and guidelines. Third, initial liver injury, as
detected by an increase in transaminases, may be transient
despite continued treatment, unless the patient has additional
factorsthatwillcausemildtoxicitytoturnintoseverehepaticdys-
function.
29 Fourth, cases of frank liver failures caused by anti-
biotics, excluding telithromycin and trovaﬂoxacin (see
hereunder), remain very rare and their number appears to be
balanced with the large use of these drugs on the one hand,
and the rate of idiopathic liver failure seen in normal adults ( 1
case for 1 million adults/year) on the other hand.
19
Lastly, the retrospective analysis of DILI cases and drug-
causality assessment remains a perilous exercise, because of
the inherently subjective nature of this approach and potential
observer biases. While instruments have been devised for a
more objective approach (the most familiar and comprehensive
being the Roussel-Uclaf Causality Assessment Method),
22,23 the
results obtained may often ﬁt rather poorly with those of the
evaluations made by the regulatory authorities,
30 creating
some confusion among professionals as well as the public. In
this context, rechallenge, often considered as a ‘gold standard’
to ascertain causality,
31 seems to us impractical and probably
unethical with outpatients, not only because of its inherent
dangers, but also because the original infection itself (which
cannot be recreated) may be an important component in the
onset of the toxic reaction.
Timing and treatment of antibiotic-induced liver injury
The interval between drug administration and the onset of
hepatic dysfunction is variable: adverse effects may develop
almost immediately, late in the course of prolonged antibiotic
treatment or several months after the cessation of therapy.
5,32
This is frequently observed with amoxicillin/clavulanate and
tetracycline,
32 and was reported for trovaﬂoxacin,
33 although
rapid onset is also seen.
33,34 Cholelithiasis associated with cef-
triaxone–calcium precipitates typically occurs only after 9–
11 days of treatment.
32 Physicians should therefore alert
patients to the warning signs of antibiotic-induced hepatotoxicity
and advise them to seek medical attention, even if symptoms
appear sometime after completing their treatment.
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of the suspected antibiotic is indicated.
4,5,35 Most patients will
then make a full recovery, but chronic liver injury is not infre-
quent.
32,35 Thus, antibiotics were the third most common
cause of chronic liver damage in a large, long-term, follow-up
registry set up in Spain.
35
Frequency and characteristics of
antibiotic-induced hepatotoxicity
Clinical studies are generally underpowered to identify trends in
hepatotoxicity, while studies undertaken to assess hepatic
signals are often complicated by numerous variables. With few
prospectivepopulation-basedstudies,casehistoriesandregistries
of spontaneous reports of adverse drug reactions are actually the
main source of toxicity data.
36 As shown in Figure 1, the incidence
and inherent risk of hepatotoxicity varies widely between anti-
biotics. Table 1 summarizes the classes of antibiotics implicated
in hepatotoxic reactions. The clinico-pathological picture can
include acute hepatocellular, cholestatic and mixed
hepatocellular-cholestatic injury, as well as chronic hepatitis,
chronic cholestatic injury, granulomas, and, in the case of intrave-
nous tetracycline, steatosis and steatohepatitis.
4
In the next sections, we will review what is known about the
hepatotoxicity of the main antimicrobials in current clinical use.
At the end of each subsection, we will also brieﬂy comment on
those antibiotics that were withdrawn because of major hepato-
toxic reactions. This may be instructive for a correct assessment
of the risks associated with the other molecules in each pharma-
cological class, and indicate what should be looked for when
dealing with drugs that are newly introduced and are therefore
less thoroughly investigated.
b-Lactams
Penicillins
Frequency
Liverinjuryisextremelyrarewithampicillin,andrarewithbenzylpe-
nicillin (penicillin G) and phenoxymethylpenicillin (penicillin V).
Amoxicillin has little hepatotoxic potential if administered alone
(see hereunder for amoxicillin/clavulanate). Transient increases in
ALT have been reported with oxacillin, carbenicillin and ticarcillin.
37
Isolated cases of Stevens–Johnson syndrome and chronic
cholestasis
38 as well as recurrent cholestasis after repeated treat-
ment
39 have been described, but these were reversible. In the UK,
reported rates of hepatic reactions to amoxicillin vary from 0.1–
0.2
5 to 3 per 100000 prescriptions.
40 Severe reactions include cho-
lestasis
41and acuteliverfailure,but casesarerare,and deaths due
to acute liver failure have not been reported.
42 The crude incidence
of ﬂucloxacillin-associated acute liver injury has been estimated as
1.8per100000prescriptions,or2.6per100000users,
43andthatof
ﬂucloxacillin-associatedjaundiceas3.6per100000prescriptions.
44
Pathology
Hepatotoxicityassociated withpenicillins ispredominantly hepato-
cellular,
37althoughcasesofcholestasiswithductopeniahavebeen
described.
38,39,41 It may frequently be confused with viral hepa-
titis.
45 Phenoxymethylpenicillinhasbeenassociatedwithincreased
serumalkalinephosphataseactivityandmildintrahepaticcholesta-
sis,
46aswellasacutehepatitiswithelevatedALT.
47Severeandpro-
longed cholestasis has been reported with benzylpenicillin,
48
including following treatment with cloxacillin,
49 and with ampicillin
in combination with the b-lactamase inhibitor sulbactam, from
which recovery took several months.
50 Cholestatic hepatitis is
more characteristic of the semi-synthetic penicillinase-resistant
oxypenicillins oxacillin, cloxacillin, dicloxacillin and, most notably,
ﬂucloxacillin.
4,5 Case reports of severe and prolonged cholestasis
with ductopenia
41,51,52are supported by epidemiological data.
40
Risk factors
Older patients and those receiving .2 weeks of treatment appear
at signiﬁcantly increased risk of ﬂucloxacillin-associated jaun-
dice.
53Thereisalsorecentevidencetosuggestageneticpredispo-
sition to ﬂucloxacillin-associated hepatotoxicity. A genome-wide
associationstudyusing866399markersin51casesofﬂucloxacil-
lin DILI and 282 controls, which were matched for sex and ances-
try, showed an association peak in the major histocompatibility
complex(MHC)regionsthatarepartofanextendedMHC57.1hap-
lotype present in ,4% of Europeans.
54
Amoxicillin/clavulanate
Frequency
Primary care physicians must be aware that the combination of
the b-lactamase inhibitor clavulanic acid with amoxicillin
Ciproﬂoxacin,
levoﬂoxacin and
moxiﬂoxacin
Tetracycline
Co-trimoxazole and
amoxicillin/
clavulanate
Erythromycin,
clarithromycin and
penicillins
Telithromycin and
trovaﬂoxacin 
Isolated cases
and
≤0.00007   
≤0.0002 ≤0.004 ≤0.02 ? 
Acute liver failure,
high mortality 
Withdrawal or severe restriction does
not allow calculating true incidences  
Figure 1. Hepatotoxicity risk of antibiotics (percentage of prescriptions for antibiotics with main indications for use in the community setting). Derived
from references 32, 37, 40, 42, 44, 73, 89, 96 and 108. Excluding antibiotics used mainly for the treatment of tuberculosis.
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JACTable 1. Frequency and characteristics of hepatotoxicity induced by antibiotics with indications for infections commonly handled initially by general practitioners and/or used for the
treatment of tuberculosis
Antibiotic Incidence Liver injury Onset Time to recovery Risk factors Comments References
Antibiotics mainly used for non-tuberculosis indications
b-Lactams
penicillins range from 1 per 2
million to 3 per
100000 prescriptions
primarily hepatocellular severe and fatal reactions extremely
rare but have been reported
5,37,40,42
oxypenicillins 1.8 per 100000
prescriptions
primarily cholestatic hepatitis both early (1–
9 weeks) after
the start of
treatment but
also delayed
following
treatment
cessation
within 12 weeks of
cessation of therapy
but up to 30%
patients have
protracted course
older age
(.55 years),
female sex,
longer duration
of treatment
ﬂucloxacillin most hepatotoxic 5,32,43,51,53
amoxicillin/clavulanate 1–17 per 100000
prescriptions
hepatocellular, cholestatic or
mixed hepatocellular-
cholestatic hepatitis
within 4 weeks of
the start of
therapy but
typically after
drug
discontinuation
within 16 weeks of
cessation of therapy
but some patients
have protracted
course
older age
(.65 years),
female sex,
prolonged and
repeated courses
hepatotoxicity associated with
clavulanic acid moiety; although
usually benign, fatalities have been
reported
32,40,42,43,56,
59,61
cephalosporins (ceftriaxone) up to 25% of adult
patients and  40%
of paediatric patients
cholelithiasis from ceftriaxone–
calcium precipitate (so-called
biliary sludge)
after 9–11 days of
treatment
within 2–3 weeks of
treatment cessation
paediatric patients,
prolonged
treatment
may mirror acute cholecystitis 32,210
Macrolides/ketolides
erythromycin ,4 cases per 100000
prescriptions
cholestatic pattern of injury with
evidence of portal and bullous
inﬂammation, eosinophilia and
mild hepatocellular necrosis
within 10–20
days of
treatment
within 8 weeks of
treatment cessation
but some patients
have protracted
course
clarithromycin has similar proﬁle and
incidence; prognosis generally good
with fatalities extremely rare
32,43,72,73,210
telithromycin unknown hepatocellular and canalicular bile
cholestasis
within a few
days of the
start of
treatment
(median
10 days)
signiﬁcant numbers of
affected patients
develop severe liver
injury, some of which
prove fatal
male sex no published incidence data but risk
of hepatotoxicity estimated 82%
greater than with other drugs
88,89,95
Fluoroquinolones
ciproﬂoxacin isolated cases hepatocellular and cholestatic
hepatitis
serious cases including fatalities
reported, though very rare
100,102,103,211
levoﬂoxacin ,1 case per 5 million
prescriptions
hepatocellular and cholestatic
hepatitis
serious cases including fatalities
reported, though very rare
107–110
moxiﬂoxacin isolated cases hepatocellular and cholestatic
hepatitis
within 3–10 days of
starting
treatment,
although delayed
onset up to
30 days after
cessation of
therapy has also
been observed
serious cases including fatalities
reported, though very rare
122
trovaﬂoxacin hepatic necrosis leading to
liver failure
variable but rapid
onset within
2 days of the start
of treatment seen
in some patients
re-exposure restricted use or market withdrawal
due to serious hepatotoxicity
32,33,128,129
R
e
v
i
e
w
1
4
3
4Sulphonamides
sulfasalazine 1 per 1000 prescriptions cholestatic or mixed
hepatocellular-cholestatic
injury
within the ﬁrst
4 weeks of
treatment
within a few weeks of
treatment
discontinuation
severe cases of hepatic injury
described including fulminant liver
failure
4,43
trimethoprim/
sulfamethoxazole
,2 per 10000
prescriptions
cholestatic or mixed
hepatocellular-cholestatic
injury
within a few weeks of
treatment
discontinuation
female sex, HIV
positive, older
age (≥75 years)
sulphonamide component responsible
for most side effects
32,135
sulfadimethoxine necrosis and granulomatous
hepatitis
rapid after
administration of
2g
138
sulfadoxine+pyrimethamine granulamatous hepatitis female sex, older
age (.65 years)
sulphonamide component of
sulfadoxine+pyrimethamine
treatment responsible for most
side effects
139
Tetracyclines
tetracycline 1 per 18 million daily
doses
microvesicular steatosis (acute
fatty liver); cholestatic,
ductopenia
long latency period female sex,
pregnancy, large
(≥1.5 g daily)
intravenous dose,
renal disease
32,143,144
doxycycline lower than tetracycline cholestatic liver injury long latency period variable with most re-exposure leads risk lower than with tetracycline 145
minocycline microvesicular steatosis (acute
fatty liver), autoimmune
hepatitis
of over a year patients recovering
on cessation of
therapy but serious
and occasionally
fatal cases reported
to recurrence 32,146,147
Antibiotics mainly used for tuberculosis
Ethambutol isolated cases but
increases in
combination with
isoniazid (6%),
rifampicin (30%) and
pyrazinamide (50%)
cholestatic hepatitis within 3–16 weeks of
treatment
within a few weeks of
treatment cessation
older age
(.60 years),
female sex,
malnutrition
rarely used alone, with most
hepatotoxicity attributed to
concomitantly administered drugs
154,182,184
Isoniazid 1%–10% of patients hepatocellular necrosis within a few days of
treatment
may resolve with
continued treatment
older age
(.60 years),
female sex,
malnutrition,
slow acetylator
status
hepatotoxicity is exacerbated with
concomitant rifampicin
administration
178,181,191
Pyrazinamide 6%–20% of patients centrolobular cirrhosis and
cholestasis
within ﬁrst 5 weeks
but may be
delayed
(.30 days)
gradual decline in
serum transaminase
levels after prompt
cessation of
treatment
older age
(.60 years),
female sex,
malnutrition,
chronic viral
hepatitis
data inconsistent on dose-related
hepatotoxicity
179,181,193–
195
Rifampicin ,2% of patients cholestatic hepatitis within 3–12 weeks gradual decline in
serum transaminase
levels after prompt
cessation of
treatment
rarely used alone,
therefore as for
other agents
potential to exacerbate hepatotoxicity
of co-administered agents
199,200,203
Streptomycin no hepatotoxic potential liver disease is a risk factor for
nephrotoxicity
212
R
e
v
i
e
w
1
4
3
5
J
A
Cmarkedly increases the risk of hepatotoxicity.
43,55 Thus, amoxicil-
lin/clavulanate is responsible for 13%–23% of drug-induced
hepatotoxicity cases
7,56,57 and is the leading cause of hospitaliz-
ation for adverse hepatic events.
7 Because symptom onset is
usually delayed,
58 early diagnosis is difﬁcult.
Hepatotoxicity is clearly linked to the clavulanic acid moiety,
with a 5- to 9-fold increase for the combination versus amoxicil-
lin alone.
40,59,60 While amoxicillin alone only slightly increases
the risk of DILI compared with non-use (adjusted odds ratio,
1.7), the amoxicillin/clavulanate adjusted odds ratio versus
non-use reaches 31.9 with recent use and 94.8 with current
use.
43 A recent retrospective case analysis of 800 patients with
drug-induced jaundice suggested that amoxicillin/clavulanate
was responsible for 32% of cases, giving an estimated incidence
rate of 9.91 cases of jaundice per 100000 prescriptions.
44
Hepatotoxicity associated with amoxicillin/clavulanate usually
follows a benign course, with symptoms resolving over several
weeks. Some patients, however, have a protracted course that
can lead to acute liver failure and death.
42 A prospective registry
study reported an unfavourable outcome (persistence of liver
injury, liver transplantation or death) in 7% of the 69 patients
who suffered amoxicillin/clavulanate hepatotoxicity.
56
Pathology
Hepatotoxicity associated with amoxicillin/clavulanate is usually
characterized by delayed cholestatic or mixed
hepatocellular-cholestatic injury.
40,59,61 This ‘hepatotoxic signa-
ture’ has, however, been challenged with evidence to suggest
that while common in older patients, younger patients are
more likely to develop hepatocellular injury than cholestatic or
mixed injury.
56
Risk factors
Prolonged or repeated courses or being .65 years of age
increases the risk of developing hepatotoxicity,
40,56 and the pres-
ence of both can increase the risk of acute liver injury to 1 per
1000 users,
40 an incidence that can be detected by primary
care physicians in everyday practice. Female sex and age
.65 years predispose individuals to amoxicillin/
clavulanate-associated jaundice.
44 A signiﬁcant association
between the DRB1*1501-DRB5*0101-DQB1*0602 haplotype and
cholestatic hepatitis related to amoxicillin/clavulanate was
reported in a pioneering Belgian study,
62 and was recently con-
ﬁrmed by the DILIGEN group from the UK.
63 A wide genome
analysis in this population is underway.
Cephalosporins
Cephalosporins are only rarely implicated in hepatotoxic reac-
tions.
64–67 Cholestasis featured in all documented cases of
cephalosporin-associated hepatotoxicity, with symptoms mani-
festing within a few days of treatment. With the exception of cef-
triaxone, for which a speciﬁc mechanism has been identiﬁed,
hepatotoxicity appears to be immunologically mediated.
68
A recent report of cefdinir-induced hepatotoxicity describes jaun-
dice, mild cholestasis with portal and lobular mixed inﬂam-
mation, and focal bile duct injury.
69
Macrolides (including azalides and ketolides)
Erythromycin
Frequency
Erythromycin-related hepatotoxicity, documented .40 years
ago, occurs with all ester derivatives.
4,5,70 According to Westphal
et al.,
45 its incidence should be considered as high; elevation of
serum aminotransferases is seen in up to 15% of cases and
overt hepatitis in  2% of patients if treated for .2 weeks.
71,72
More recent reports, however, suggest that it remains much
lower
73 and similar to that of penicillin V.
74 A retrospective
cohort study using the UK General Practice Research Database
(GPRD) estimated the risk of cholestatic hepatitis as 3.6 cases
per 100000 users.
73 Hospitalization for symptomatic acute
hepatitis is rare (a US study reported 2.28 cases for every
1 million patients receiving a 10 day course of erythromycin).
75
To our knowledge, there has been only one documented fatal
outcome with erythromycin, which occurred in an elderly male
patient treated with intravenous erythromycin lactobionate.
76
Pathology
Erythromycin-induced hepatotoxicity probably arises from a
combination of intrinsic hepatotoxic effects and the hypersensi-
tivity reactions that characterize most cases of liver injury. A cho-
lestatic pattern of injury is typical, but most cases also have
evidence of hepatocellular injury.
72 Prognosis is generally good,
with symptoms and biochemical abnormalities resolving within
2–5 weeks of treatment discontinuation; very occasionally, cho-
lestasis persists for 3–6 months.
4 Actually, all 32 patients with
erythromycin-associated hepatocellular injury in the Swedish
registry survived, compared with the 40% mortality in
halothane- and naproxen-induced hepatocellular damage.
25
Clarithromycin
The hepatotoxic proﬁle of clarithromycin appears similar to that
of erythromycin.
43 The ﬁrst report of cholestatic hepatitis
77 was
followed by a brief report of reversible cholestatic hepatitis in 5
of 14 elderly patients taking high-dose clarithromycin.
78 Two
cases of fulminant hepatic failure have been associated with
clarithromycin, one of which required liver transplantation,
79
while the second, a fatal case, was attributed to an interaction
between clarithromycin and concomitant disulﬁram.
80
However, infrequent severe hepatic dysfunction and liver failure
resulting in death appear in the US labelling for clarithromycin.
81
Azithromycin
Adverse hepatic events associated with azithromycin (an azalide
closely related to the macrolides but with a considerably longer
half-life and extended tissue accumulation) are rare. Reversible
azithromycin-related intrahepatic cholestasis has recently been
reported in isolated cases,
82–85 while association between azi-
thromycin and asymptomatic elevated liver enzymes in treated
children is well documented.
86
Review
1436Telithromycin
Telithromycin is the ﬁrst, and so far the only, ketolide approved
for clinical use. It was primarily designed for activity against
macrolide-resistant S. pneumoniae
87 and, in this context,
should have perhaps been restricted to situations where this
would have conferred a decisive advantage, i.e. for severe infec-
tions in regions where resistance to macrolides is high. In Phase
III trials, mild-to-moderate increases in ALT were observed at a
higher frequency than in the placebo arm. Subsequent to com-
mercial launch in the USA, three cases of serious liver injury
with jaundice and signiﬁcantly elevated liver enzymes
(.10×ULN in one case) occurred in patients having received teli-
thromycin for minor upper respiratory tract infections. One
patient spontaneously recovered, while the second required
liver transplantation and the third died.
88 An initial analysis of
12 cases provided evidence for a rare, unusual form of hepato-
toxicity characterized by short latency, systemic symptoms
and, in some cases, signiﬁcant ascites.
89 The FDA then issued a
warning about the potential for serious liver toxicity, a drastically
restricted indication (sole use in community-acquired pneumo-
nia)
11 and a boxed warning in the US product labelling.
90 This
decision has been reinforced by additional case reports to the
FDA’s Medwatch.
21,96 In parallel, the EMA introduced ‘alterations
in hepatic enzymes, cases of severe hepatitis, and liver failure’ in
the ‘Special warnings’ section of the ‘Summary of Product
Characteristics’ (SPC), but maintained indications for both
community-acquired pneumonia and acute exacerbation of
chronic bronchitis (for the latter, however, only if the infection
is caused by known or suspected b-lactam- and/or
macrolide-resistant strains).
91–93
Frequency
Thewarningsdiscussedabovehaveresultedinamarkedreduction
in the prescription of telithromycin, making epidemiological
studies difﬁcult. Analysisof the FDA post-marketing database indi-
cates a reporting rate of 167 cases of acute liver failure per 1
million person-years of telithromycin use (versus an expected
value of 1 case per 1 million person-years).
94 The manufacturer
reports an incidence of 7 cases of telithromycin-induced hepatitis
per 10000 people treated.
90 The FDA Adverse Event Reporting
System shows that the risk of hepatotoxicity is 82% greater with
telithromycin than with other agents.
95 The EMA mentions that
an increase in liver enzymes is common, hepatitis uncommon
and cholestatic jaundice rare, while the frequency of severe hepa-
titisandliverfailurecannotbeestimatedfromtheavailabledata
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(EMA categorizes adverse effects as common, uncommon, rare
and very rare based on frequencies of ≥1/100 to ,1/10, ≥1/
1000 to ,1/100, ≥1/10000 to ,1/1000 and ,1/10000 of
treated patients, respectively).
Pathology
Telithromycin-related liver injury is characterized by rapid onset
of symptoms (consistent with rapid-onset hypersensitivity),
including jaundice, fever, abdominal pain and, on occasion,
ascites.
21,96,97 Of 42 cases of telithromycin-induced hepatotoxi-
city recently described, 25 developed jaundice and met criteria
for Hy’s Law, 32 were hospitalized, 14 had severe liver injury
(grade 4 and 5), 1 required transplantation, and 4 died.
96
Re-exposure to telithromycin caused recurrent acute hepatitis
in a patient who had experienced adverse hepatic effects with
a previous course.
97
Fluoroquinolones
Fluoroquinolones achieve high concentrations in bile, which
makes them well suited to the treatment of bacterial cholecysti-
tis and cholangitis. Modest increases in serum ALT levels can be
considered as a ﬂuoroquinolone class effect. More severe liver
injury remains rare (but see below for information on trovaﬂoxa-
cin). In fact, there have been only few reports of signiﬁcant hepa-
totoxicity, even when used in patients with advanced liver
disease.
5,98 Fluoroquinolones, such as moxiﬂoxacin and levoﬂox-
acin, are used off-label as alternative drugs in antituberculosis
regimens, but neither drug appears to cause additional hepato-
toxicity in this patient population.
99
Ciproﬂoxacin
The literature remains scanty over the potential hepatotoxicity of
ciproﬂoxacin, and the incidence of ciproﬂoxacin-induced hepato-
toxicity is considered very low,
4,5 although two fatal cases of
acute liver failure in elderly men have been documented.
100,101
Cases of hepatocellular injury (n¼51) and cholestatic hepatitis,
with or without ductopenia,
102,103have been described following
treatment with ciproﬂoxacin. A recent report also highlights a
case of simultaneous acute cholestatic liver injury and renal
failure, which resolved within 5 months of discontinuing treat-
ment.
104 The recently harmonized European SPC of ciproﬂoxa-
cin
105 mentions only cases of severe hepatotoxicity in the
‘Special warnings’ section, which needs to be seen in the
context of a very large use of this drug worldwide. The SPC
further mentions that an increase in transaminases and bilirubin
is uncommon, hepatic impairment, cholestatic icterus and hepa-
titis rare, and liver necrosis (very rarely progressing to life-
threatening hepatic failure) very rare, based on both oral and
intravenous administration of ciproﬂoxacin.
Levoﬂoxacin
The incidence of adverse hepatic effects associated with levo-
ﬂoxacin, an extended-spectrum ﬂuoroquinolone, is also low.
Abnormal liver function occurred in ,1% of patients in clinical
trials,
106 while post-marketing surveillance revealed rates of
severe liver injuries (hepatitis, necrosis and hepatic failure)
of ,1 case per 5 million prescriptions.
107 Nonetheless, cases of
levoﬂoxacin-related liver injury have been reported, including
cases of hepatic failure.
108–113 The US prescribing information
mentions that severe, and sometimes fatal, hepatotoxicity not
associated with hypersensitivity has been reported.
114
Moxiﬂoxacin
Frequency
Reviews of clinical trials and post-marketing surveillance studies
indicate minimal incidence of hepatic injury, though liver func-
tion tests may be abnormal in  1%–5% of patients.
115,116
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emerged in either clinical trials or post-marketing surveillance,
and published data have remained scanty for many
years,
117,118 there have been spontaneous reports of hepatocel-
lular injury. These include eight deaths due to hepatic failure
where a link to moxiﬂoxacin could not be excluded
119 and a
more recent case where it was considered to be idiosyncratic.
120
This has been introduced as an amendment by the EMA in the
European SPC,
121 but such fatal cases should be seen in the
context of 85 million treatments with moxiﬂoxacin worldwide
at that time.
122 The current, revised SPC mentions elevation of
transaminases as being common, hepatic alteration uncommon,
and icterus and hepatitis rare. Moxiﬂoxacin is not included in the
list of drugs identiﬁed in at least ﬁve adjudicated cases of
DILI.
123 Moxiﬂoxacin, as for levoﬂoxacin, was also found to
cause no additional hepatotoxicity when used by patients with
hepatitis induced by ﬁrst-line antituberculosis drugs.
99
Pathology
Liver injuries induced by moxiﬂoxacin are typically cholestatic or
mixed hepatocellular-cholestatic rather than hepatocellular.
Symptoms are usually evident within 3–10 days of starting mox-
iﬂoxacin, although delayed onset of up to 30 days after cessation
of therapy has also been observed. A case of moxiﬂoxacin-
associated drug hypersensitivity syndrome with toxic epidermal
necrolysis and fulminant fatal hepatic failure has been
described.
124
Gemiﬂoxacin, gatiﬂoxacin and trovaﬂoxacin
Gemiﬂoxacin is approved in the USA and a few other countries,
but not in Europe. To date, there has been no report of hepato-
cellular injury with gemiﬂoxacin, but this may reﬂect its very
limited patient exposure.
125 Gatiﬂoxacin was approved in the
USA and other countries, but not in Europe. It has been recently
withdrawn, mainly for adverse glycaemic effects. Gatiﬂoxacin,
however, was also implicated in several cases of hepatotoxicity,
with 27 occurrences reported to the FDA (cited in 11 cases as the
most probable cause of death).
126 Trovaﬂoxacin was approved in
the USA in 1998, but post-marketing surveillance quickly
revealed signiﬁcant, serious hepatotoxicity,
127 with clear signs
of eosinophilic inﬁltration, hepatocellular vacuolar degeneration
and necrosis.
128 Thus, within 2 years (with only 2.5 million
patient exposures), 140 cases of serious hepatic events, including
14 cases of acute liver failure, 4 cases requiring liver transplan-
tation and 5 deaths, were reported.
127,129 The drug was, there-
fore, restricted to serious and life- or limb-threatening
infections.
127,129,130 Although approved in Europe, the drug was
quickly withdrawn by its registration holder before its actual
commercial launch. The greater hepatotoxic potential of trova-
ﬂoxacin may be due to its diﬂuorophenyl side chain (shared
with temaﬂoxacin, also withdrawn for adverse hepatic
effects
33), but the cyclopropylamine moiety (speciﬁc to trovaﬂox-
acin) could also play an important role.
131 Trovaﬂoxacin was also
shown to sensitize hepatocytes to TNF-a-induced death,
132 an
effect not seen with levoﬂoxacin in comparative studies.
133
These clear structural relationships imply that the hepatotoxicity
of trovaﬂoxacin is unlikely to be the extreme of a ﬂuoroquinolone
class effect.
Sulphonamides
The hepatotoxicity of the sulphonamides, the oldest class of anti-
biotics, is well documented.
134 This class includes sulfamethoxa-
zole, sulfasalazine, sulfamethizole and sulfamethoxypyridazine,
as well as the combinations trimethoprim/sulfamethoxazole
and pyrimethamine/sulfadoxine.
Frequency
Sulfasalazine emerged as one of the most hepatotoxic drugs in a
recent population-based case–control study using the UK-based
GPRD, with an incidence approaching 1 per 1000 users,
43 i.e.
similar to amoxicillin/clavulanate. Sulfasalazine hepatotoxicity
is frequent enough to be detected at the primary care level.
Most cases of sulphonamide-induced hepatotoxicity are mild
and patients usually recover within a few weeks of treatment
discontinuation,
2 but severe cases, including fulminant liver
failure, have been described for the combination trimethoprim/
sulfamethoxazole.
135,136
Pathology
Sulphonamides most often induce cholestatic or mixed
hepatocellular-cholestatic injury,
2,137 although cases of necrosis
and granulomatous hepatitis have also been described.
135,138,139
The sulphonamide component is thought to be responsible for
most hepatic side effects with trimethoprim/sulfamethoxazole.
The underlying mechanism, explaining the idiosyncratic charac-
ter of the toxicity, could be its slow acetylation in some patients,
preventing its normal elimination and allowing it to enter into
other catabolic pathways related to toxicity.
139a A case of jaun-
dice and acute liver failure occurred in a patient receiving tri-
methoprim/sulfamethoxazole for a urinary tract infection;
however, liver function returned to normal over a 2 month
period, without intervention.
140
Tetracyclines
Frequency
Tetracycline hepatotoxicity, ﬁrst described .50 years ago,
141
seems related to the use of large doses
142 and, contrary to
most other antibiotics, is predictable and reproducible in
animal models.
45 With normal, low, oral doses, tetracyclines
only rarely cause liver injury ( 1 case per 18 million daily
doses according to early estimates,
143 and 3.7 cases per
100000 users or 1.5 cases per 100000 prescriptions in more
recent surveys), representing one of the lowest rates for which
a signiﬁcant association of liver injury and antibiotic use has
been established.
43 Early reports (including one death) of an
association between tetracycline hepatotoxicity and pregnancy
all related to high-dose intravenous treatment.
144 A later
survey suggested that female sex was not a risk factor with
low-dose oral tetracycline therapy and, importantly, did not
increase the risk of death due to hepatic side effects.
143
Doxycycline is less hepatotoxic than tetracycline, with no
increased risk compared with controls in a retrospective
study (current use odds ratio, 1.49; 95% conﬁdence interval,
0.61–3.62).
145 A recent fatal case has been described,
113 but
Review
1438after exposure to levoﬂoxacin and in association with naproxen.
Rarely, minocycline-associated hepatotoxicity has necessitated
liver transplantation or proved fatal.
5,146 No public report of
tigecycline-related DILI has been identiﬁed to date.
Pathology
Microvesicular steatosis was the characteristic feature of treat-
ment with intravenous or large oral doses of tetracycline,
142
whereas cholestasis was the predominant clinico-pathological
pattern with oxytetracycline and minocycline.
43 Long-term min-
ocycline use as a treatment for acne has also been associated
with autoimmune hepatitis, characterized by antinuclear auto-
antibodies, a lupus-like syndrome, fatigue, rash and arthralgia,
96
and hypersensitivity syndrome.
147
Linezolid
Linezolid treatment is most often initiated in the hospital, but,
because of its excellent bioavailability in its oral form, linezolid
treatment is often extended to home therapy after discharge
and,therefore,isunderthecontrolofthegeneralpractitioner.Pro-
longed treatment with linezolid has been associated with severe
liver failure and lactic acidosis, with liver biopsy showing microve-
sicular steatosis.
148 These alterations were related to the known
mitochondrial dysfunction induced by linezolid,
149 but no further
details have been disclosed so far. In two recently published
studies from Japan, chronic liver disorders (liver cirrhosis and
hepatitis),
150 on the one hand, and high pre-treatment levels of
total bilirubin and transaminases and coexistence of chronic
liver disease (CLD), on the other hand,
151 were found to be signiﬁ-
cantriskfactorsforthedevelopmentofthrombocytopenia,awell-
known side effect of linezolid that most commonly develops after
≥14 days of treatment.
150 As thrombocytopenia is itself a
common complication in patients with CLD,
152 it is possible that
somesortofsynergisticeffectand/oranenhancementoflinezolid
toxicity is occurring due to a reduction in its metabolism.
151
Although there is evidence that linezolid accumulates in bile,
153
there are insufﬁcient data to provide speciﬁc recommendations
about potential side effects at this time.
Antituberculosis drugs
Although prescribed by specialist practitioners, antituberculosis
drugs are most often used today in outpatients. Thus, primary
care physicians are among the ﬁrst professionals to see potential
side effects, including liver damage.
First-line treatment of adult respiratory tuberculosis entails
8 weeks of combination therapy with isoniazid, pyrazinamide
and rifampicin, followed by 16 weeks of isoniazid and rifampicin,
to which ethambutol is usually added. Streptomycin is used in
cases of retreatment,
154 with ﬂuoroquinolones reserved for
second-line use in drug-resistant tuberculosis or as substitutes
in patients unable to tolerate ﬁrst-line agents.
99,155 These drugs
have been used for many years, and have known and well-
documented adverse effects on the liver that range from asymp-
tomatic increases in liver enzymes to acute hepatitis and
fulminant hepatic failure.
156 Most commonly associated with iso-
niazid, pyrazinamide and rifampicin, they usually occur within the
ﬁrst few weeks of the intensive phase of therapy,
154,155,157 are
among the most common of all adverse events,
158 and are
responsible for most premature discontinuations due to adverse
events.
159 The hepatotoxicity of antituberculosis drugs has
already been the subject of several recent reviews
154,155,160 and
will, therefore, be covered here only brieﬂy. Because treatment
of active tuberculosis entails concomitant use of more than one
drug, it is difﬁcult to identify the hepatotoxic effect of any individ-
ual drug in the combination regimen. Thus, we will ﬁrst review the
generalriskfactorsidentiﬁedinpatientsreceivingantituberculosis
treatment and then brieﬂy review each drug individually.
General risk factors
Older age (.60 years), female sex and malnutrition (low body
mass index) are widely accepted risk factors for drug-induced
hepatotoxicity among tuberculosis patients.
154,157,161–166 Pre-
existing liver disease, such as chronic viral hepatitis, would
seem a likely risk factor and has been identiﬁed in some,
154,167
but not all,
168,169 studies. Similarly, inconsistent ﬁndings have
been reported for co-infection with HIV.
154,170–172 Acetylator
status may predispose to an increased risk of drug-induced
hepatotoxicity, with several studies showing increased risk in
slow versus fast acetylators,
173–177 although contradictory
but less recent results have also been reported.
178,179 In
addition to the N-acetyltransferase 2 slow acetylator genotype,
other potential risk genotypes for hepatotoxicity include
CYP2E1 polymorphisms.
176,177 Excess alcohol consumption is
thought to predispose to an increased risk of drug-induced hepa-
totoxicity and, in one study, was found to exacerbate hepatotoxi-
city in patients with chronic hepatitis C infection.
167 Lastly,
concomitant administration of other hepatotoxic drugs, such
as acetaminophen (paracetamol), can also increase the risk of
hepatotoxicity.
180
Ethambutol
Frequency
Ethambutol-associated hepatotoxicity is considered rare.
181 A
recent study, in which ethambutol alone or in combination
with ﬂuoroquinolones and streptomycin was used to manage
hepatotoxicity secondary to standard ﬁrst-line drugs, showed
no additional drug-induced hepatotoxicity.
99 Previous studies
suggest that the incidence is lowest when ethambutol is com-
bined with streptomycin and isoniazid,
182,183 whereas in one
small series, 50% of patients experienced drug-induced hepato-
toxicity when ethambutol was combined with pyrazinamide.
184
Pathology
Ethambutol is not considered hepatotoxic, although a few iso-
lated cases of hepatic injury and one of cholestatic hepatitis
have been described.
181
Isoniazid
Frequency
Isoniazid, used for both active treatment and prophylaxis of
latent tuberculosis, has known hepatotoxic potential that has
Review
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zine.
154,185 About 10% of patients experience increases in
serum transaminase levels during treatment, with  1%–2%
developing symptomatic hepatitis.
178,181 Signiﬁcantly higher
rates of symptomatic hepatitis have been described in compari-
son with rifampicin (1.8% versus 0.08%, P,0.001; 4% versus
0.7%, P¼0.003) as well as lower rates of treatment completion
due to poorer tolerability.
186,187However, the frequency of severe
hepatotoxicity appears signiﬁcantly less common with isoniazid
than with rifampicin in combination with pyrazinamide.
188,189
Similarly, rates of hepatotoxicity are reportedly higher when iso-
niazid is co-administered with rifampicin
181 (as a potent inducer
of the hepatic CYP450 system, rifampicin can increase pro-
duction of reactive metabolites of isoniazid and thereby increase
the risk of hepatotoxicity
154,190,191).
Pathology
Liver injury is characterized by hepatocellular necrosis and
degeneration, such as hepatocyte ballooning, as well as mild
inﬂammatory inﬁltrates within the portal tracts and, less com-
monly, cholestasis.
181 In six cases of fulminant hepatitis follow-
ing isoniazid/rifampicin combination therapy, centrilobular
necrosis was the principal hepatic lesion.
190
Pyrazinamide
Frequency
Introduced into clinical practice in the 1950s, pyrazinamide has
known hepatotoxic potential; increases in serum transaminase
levels and symptomatic hepatitis occur in 10%–20% of
patients.
181 Originally attributed to high initial dosage regimens,
the relationship between pyrazinamide dosage and frequency of
hepatotoxicity remains controversial. Early reports of no associ-
ation between higher dosage and increased hepatotoxicity
192
have been supported by a recent meta-analysis
193 and a
case–control study of dosing schedules.
194 While this issue
remains unresolved, several studies point to a higher frequency
of hepatotoxicity in regimens containing pyrazinamide than in
those containing only isoniazid and rifampicin.
179,195,196 In one
series, drug-induced hepatotoxicity was almost twice as frequent
with pyrazinamide as compared with non-pyrazinamide regi-
mens.
179 In another study, the estimated risk of hepatotoxicity
was 2.8% for pyrazinamide-based regimens, compared with
0.8% for concomitant isoniazid and rifampicin therapy.
196 The
inclusion of pyrazinamide in retreatment regimens also
appears to increase the risk of hepatotoxicity, with rates of
24% in one series as compared with none in the isoniazid, rifam-
picin, ethambutol and streptomycin treatment arm.
197
Pathology
Extensive centrolobular necrosis has been described in one
case,
198 while the key pathological features in a case of fatal
liver failure consisted of bridging necrosis, lymphocyte inﬁltration,
focal cholestasis, increased ﬁbrosis and micronodular
cirrhosis.
154
Rifampicin
Frequency
Compared with isoniazid and pyrazinamide, rifampicin has a
lower propensity to cause hepatotoxicity,
181 with ,2% of
patients experiencing increased serum transaminase levels in a
recent study.
199 This is consistent with earlier data, in which
the incidence of hepatotoxicity was 1.5% for rifampicin versus
4% and 5% for isoniazid and pyrazinamide, respectively.
200 In
a meta-analysis of pooled data on .3500 patients, severe hepa-
totoxicity occurred in 0%–0.7% of patients treated with rifampi-
cin versus 1.4%–5.2% of isoniazid-treated patients.
201 Although
hepatotoxicity attributed to rifampicin itself is rare, it may con-
tribute to increased hepatotoxicity when co-administered with
isoniazid and, especially, pyrazinamide.
202 In one study, rifampi-
cin in combination with pyrazinamide signiﬁcantly increased
rates of treatment interruption for hepatotoxicity as compared
with isoniazid alone (10% versus 2.5%; P¼0.007).
203 In
another study, mild hepatotoxicity (grade 1 or 2) was more fre-
quent in patients receiving a higher dose of rifampicin in combi-
nation with pyrazinamide than with the standard dose (46%
versus 20%; P¼0.054).
204
Pathology
The histopathological picture is one of spotty-to-diffuse hepato-
cellular necrosis primarily associated with cholestasis.
154,181 In
some cases it can lead to liver failure.
205
Streptomycin
Frequency
Of the current ﬁrst-line drugs, streptomycin has little or no hepa-
totoxic potential; however, it can cause nephrotoxicity,
181 as is
the case for all aminoglycosides.
206 Patients with liver disease
are more susceptible to aminoglycoside-induced nephrotoxi-
city,
212 meaning that acute renal failure is prognostic for acute
liver failure (in this setting, acute renal failure may precipitate
hepatic encephalopathy). Potentially, the inclusion of streptomy-
cin in antituberculosis regimens may alter the course, if not the
frequency, of fulminant hepatitis due to isoniazid- or
pyrazinamide-induced hepatotoxicity.
181
Conclusions
Antibiotic-induced hepatotoxicity produces an array of hepatic
lesions that are often clinically indistinguishable from those of
hepatobiliary diseases, making causality difﬁcult to establish.
While the temporal relationship between drug administration
and onset of hepatic symptoms and exclusion of competing
aetiologies may help, in most cases diagnosis is largely circum-
stantial. Delayed onset of hepatic dysfunction after cessation
of therapy, which has been reported with several antibiotics,
complicates the picture further, especially in cases of fatal liver
failure. It is also difﬁcult to determine cause and effect when
there are only a few isolated spontaneous reports. Amoxicillin/
clavulanate (due to the clavulanic acid component),
co-trimoxazole (due to the sulphonamide component) and ﬂu-
cloxacillin appear as the most frequently involved drugs among
Review
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sely, no other currently approved antibiotic that is in use in
general practice, except for telithromycin, can be singled out to
be overly hepatotoxic.
Antibiotics are a vital weapon in combating serious bacterial
infections. To maximize the beneﬁt-to-risk ratio of antibiotic
therapy, it is vital to ensure that the appropriate patients are
treated with the most suitable drugs. In this respect, it is critical
to be vigilant for potential risk factors that may increase the like-
lihood of a patient experiencing adverse hepatic events, namely
the choice of the drug (see above) and patient factors. The latter
mainly include a previous experience of hepatic dysfunction with
the same antibiotic drug, the co-administration of other drugs
known to cause hepatotoxic reactions, a pre-existing hepatic
insufﬁciency without close monitoring of the hepatic function
and, depending on the drug, one of several other risk factors,
as listed in the paper and summarized in Table 1. Although
antibiotic-induced hepatotoxicity is a rare event, and serious
events are exceptionally rare, it is important to understand
that most antibiotics can cause idiosyncratic hepatotoxic reac-
tions. Both physicians and patients need to be aware of, and
monitor for, potential symptoms and take prompt action if
signs of hepatotoxicity emerge. This remains probably the only
and most effective course of action until pharmacogenetic
testing, which several organizations are working on
29,207,208
and which already shows promise for a few other drugs,
209
becomes available on an ‘easy-to-use’ basis for prospectively
identifying those patients susceptible to antibiotic-induced liver
injury in daily clinical practice.
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